Table 1 Comparison of patient and tumor characteristics between the two study groups
Variable | Categories | Definitive | Adjuvant | P-value* |
|---|---|---|---|---|
T stage | T3 | 46 (71.9) | 21 (58.3) | 0.112 |
T4a | 13 (21.3) | 14 (40) | ||
T4b | 2 (3.3) | 0 (0) | ||
N stage | 0 | 31 (48.4) | 16 (44.4) | 0.884 |
1 | 10 (15.6) | 5 (13.9) | ||
2 | 18 (28.1) | 13 (36.1) | ||
3 | 5 (7.8) | 2 (5.6) | ||
Stage | III | 32 (50) | 13 (36.1) | 0.300 |
IVa | 27 (42.2) | 21 (58.3) | ||
IVb | 5 (7.8) | 2 (5.6) | ||
Completion of RT | Yes | 58 (90.6) | 31 (86.1) | 0.498 |
No | 6 (9.4) | 5 (13.9) | ||
Chemotherapy before RT | Yes | 11 (17.2) | 4 (11.1) | 0.414 |
No | 53 (82.8) | 32 (88.9) | ||
Concurrent systemic therapy | Yes | 55 (85.9) | 18 (50) | < 0.001 |
No | 9 (14.1) | 18 (50) | ||
Regimen of concurrent systemic therapy | Cisplatin, weekly | 33 (60) | 16 (88.9) | 0.108 |
Cisplatin, triweekly | 20 (36.4) | 2 (11.1) | ||
Erbitux | 2 (3.6) | 0 | ||
Systemic therapy compliance (when indicated) | Yes | 38 (69.1) | 7 (38.8) | < 0.001 |
No | 17 (30.9) | 11 (61.2) |